Vigafyde is a drug owned by Pyros Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2024 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 17, 2042. Details of Vigafyde's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12290499 | Vigabatrin liquid pharmaceutical composition |
Oct, 2042
(16 years from now) | Active |
| US12016857 | Stable liquid vigabatrin pharmaceutical composition for oral dosage |
Aug, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Vigafyde's patents.
Latest Legal Activities on Vigafyde's Patents
Given below is the list of recent legal activities going on the following patents of Vigafyde.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 06 May, 2025 | US12290499 |
| Recordation of Patent eGrant | 06 May, 2025 | US12290499 |
| Email Notification | 06 May, 2025 | US12290499 |
| Recordation of Patent Grant Mailed | 06 May, 2025 | US12290499 |
| Mail Patent eGrant Notification | 06 May, 2025 | US12290499 |
| Patent Issue Date Used in PTA Calculation | 06 May, 2025 | US12290499 |
| Email Notification | 17 Apr, 2025 | US12290499 |
| Issue Notification Mailed | 16 Apr, 2025 | US12290499 |
| Dispatch to FDC | 07 Apr, 2025 | US12290499 |
| Application Is Considered Ready for Issue | 07 Apr, 2025 | US12290499 |
US patents provide insights into the exclusivity only within the United States, but
Vigafyde is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vigafyde's family patents as well as insights into
ongoing legal events
on those patents.
Vigafyde's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vigafyde's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 17, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vigafyde Generic API suppliers:
Vigabatrin is the generic name for the brand Vigafyde. 21 different companies have already filed for the generic of Vigafyde, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vigafyde's generic
About Vigafyde
Vigafyde is a drug owned by Pyros Pharmaceuticals Inc. Vigafyde uses Vigabatrin as an active ingredient. Vigafyde was launched by Pyros in 2024.
Approval Date:
Vigafyde was approved by FDA for market use on 17 June, 2024.
Active Ingredient:
Vigafyde uses Vigabatrin as the active ingredient. Check out other Drugs and Companies using Vigabatrin ingredient
Dosage:
Vigafyde is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/ML | SOLUTION | Prescription | ORAL |